Navigation Links
MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
Date:8/19/2007

diabetes mellitus within

4-12 months of diagnosis

Pancreatic Led by Dr. Bernhard http://www.clinicaltrials.gov

islet cell Hering of the University (search for NCT00265473)

transplantation of Minnesota, this Phase

with teplizumab 2 trial funded by NIDDK

induction is enrolling patients

therapy less than 40 years old

who have been insulin

dependent for more

than 5 years

About Teplizumab

Teplizumab, also called MGA031 and hOKT3-gamma-1 (Ala-Ala), is a humanized monoclonal antibody engineered to alter the function of the T lymphocytes that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T cells and by doing so, may modulate the immunologic response that causes disease.

About Type 1 Diabetes

Type 1 diabetes is an autoimmune disease in which the body's immune system attacks and destroys the insulin-producing beta cells of the pancreas. The symptoms associated with type 1 diabetes can appear suddenly and leave a person dependent on injected insulin for life. The disease carries the constant threat of devastating complications such as heart and kidney disease, nerve damage and blindness. Although diagnosis most often occurs in childhood and adolescence, the disease can strike adults as well. Individuals with type 1 diabetes must test their blood sugar four or more times per day and take multiple insulin injections daily or continually infuse insulin through a pump. While trying to balance insulin doses with their food intake and daily activities, people with this form of diabetes must always be prepared for serious hypoglycemic (low blood sugar) and hyperglycemic (high blood sugar) reactions, both
'/>"/>

SOURCE MacroGenics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
4. Global Rabies Treatment May be Possible with NanoViricides Drugs
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Ore. , Aug. 29, 2014 /PRNewswire-iReach/ -- ... Accessory (Axilla) Strap for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today ... voluntary recall to address a potential issue with ... used for the Axilla application of the SAM ...
(Date:8/29/2014)...  A Boston Scientific Corporation (NYSE: ... and preliminary long term stricture resolution of benign ... issue of the peer-reviewed journal, Gastroenterology. ... conducted in 11 countries and five continents, and ... (FCSEMS) after extended indwell (i.e., up to 12 ...
(Date:8/29/2014)... 2014 Medina Medical announced today that Mr. ... the Board of Directors on August 18, 2014. Mr. ... commercialization experience, including over a decade of direct experience ... a Partner of the medical device incubator The Foundry, ... Foundry start-ups. Mr. Engelson previously served as the Chief ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2
... 20 Today, Family Research,Council President Tony Perkins ... Shinya Yamanaka. Thomson, the first to grow human ... in the journals Science,and Cell, respectively, showing that ... human skin cells, without first creating or,destroying human ...
... International,Corporation (Nasdaq: PRXL ), a ... Dr. Victor Kiri, formerly with GlaxoSmithKline,as ... Clinical Research,Services business. Dr. Kiri,s responsibilities ... conduct of comparative observational studies, offering,epidemiological ...
Cached Medicine Technology:PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri 2PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri 3PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri 4
(Date:8/30/2014)... Acne is a common problem millions of American ... more than a daily nuisance, for some, it can have a ... can even lead to dramatic mood swings and depression. , ... clear up their skin. In some cases, that can make the ... and error, those on a quest for clearer skin can now ...
(Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... incretin mimetic claims continue to move forward in U.S. ... issued by AstraZeneca PLC on July 31, 2014, Byetta ... named in 409 product liability claims that allege the ... documents indicate that many of these claims are pending ...
(Date:8/30/2014)... HealthDay Reporter FRIDAY, Aug. 29, ... on for broken bones or other orthopedic trauma shops around ... Less-educated patients and patients who had used narcotic painkillers ... said study lead author Dr. Brent Morris, a shoulder and ... suggests that doctors aren,t talking to one another about the ...
(Date:8/30/2014)... "My wife suffered neck, back and spine injuries ... of two inventors from Bethel, Alaska. "The whiplash contributed ... area. She tried other pillows to little avail. The ... comfort and providing extra sleep." , They created a ... head, neck and back comfortably. This enables the user ...
(Date:8/30/2014)... PA (PRWEB) August 30, 2014 "My ... sleep knowing that, at any moment, her fever might ... order to keep me well aware of how she ... developed the TEMP ALARM to continuously monitor a child's ... develops a fever. This ensures that prompt medical care ...
Breaking Medicine News(10 mins):Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3
... poor heart health, how to diagnose disease early and other tips to prolong ... ... a principle cause of death in dogs, affecting more than 10 percent of ... site devoted to this issue - www.yourdogsheart.com - is designed to ...
... method of assessing the quality of phase I ... conferences: EORTC-NCI-AACR (ENA) [1] and American Society of ... (23 October) at the 20th ENA Symposium on ... there is room for improvement and the researchers ...
... ... for hospitals, COLUMBUS, Ga., Oct. 21 As more hospitals ... survey(i) by,insurance provider Aflac finds that 86 percent of nurses say ... determining where,they choose to work, and more than half report they ...
... Vista Partners announced today,that it has updated coverage ... its $8.50 price. "MediciNova recently announced positive,preliminary data ... sizable,percentage of the asthma market potentially resulting in ... Medicinova,s other clinical,candidate, MN-166, is intended for the ...
... 21 Some 2.3 million,children a year, mostly from ... pay for preventive or other medical needs, even though ... a new study supported,by HHS, Agency for Healthcare Research ... of HHS, National Institutes of Health., The new ...
... The fifty-year-old program,s difference: Melting stored fat and increasing ... the body,s metabolism for ... of economic,instability, there is a different type of belt tightening going ... Green Valley Spa,has become the first destination spa in the U.S. ...
Cached Medicine News:Health News:New Web Site Devoted to Canine Heart Disease - A Leading Cause of Death in Dogs 2Health News:Assessing the quality of phase I clinical trial abstracts 2Health News:Assessing the quality of phase I clinical trial abstracts 3Health News:Nurses Report Quality Health Benefits Key to Choosing an Employer 2Health News:Vista Partners Updates Coverage on MediciNova Inc. (NASDAQ: MNOV); Maintains $8.50 Price Target 2Health News:More Than 2 Million Children With Insured Parents Are Uninsured; Most Are Low or Middle Income 2Health News:More Than 2 Million Children With Insured Parents Are Uninsured; Most Are Low or Middle Income 3Health News:Green Valley Spa Now Offers hCG Weight Loss Therapy 2
... an extremely accurate digital A-scan system. The ... probe and fast precise algorithm enables scan ... along the visual axis. The A5500 A-scan ... monitor, built-in thermal printer, 5 different examination ...
... is extremely portable, weighing slightly more than ... system provides a large liquid crystal display. ... noise probe and fast precise algorithm enables ... probe along the visual axis. The Microscan ...
... Accurate, efficient and easy to use. The ... variety of regressive, theoretical, and adaptive IOL ... the patient. Convenient design features improve your ... hands-free operation, audible tone to minimize corneal ...
... Ultrasonic A-Scan offers so many ... package. Besides,its compact and lightweight ... measurement and easy operation.,Furthermore, it ... and manual gate.,NIDEK is proud ...
Medicine Products: